We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




PSA Gene Variants Distinguish Patients with Highly Aggressive Prostate Cancer

By LabMedica International staff writers
Posted on 15 Oct 2014
Print article
Image: GS3 prostate cancer: The tissue still has recognizable glands, but the cells are darker. At high magnification, some of these cells have left the glands and are beginning to invade the surrounding tissue or having an infiltrative pattern. This corresponds to a moderately differentiated carcinoma (Photo courtesy of Wikimedia Commons).
Image: GS3 prostate cancer: The tissue still has recognizable glands, but the cells are darker. At high magnification, some of these cells have left the glands and are beginning to invade the surrounding tissue or having an infiltrative pattern. This corresponds to a moderately differentiated carcinoma (Photo courtesy of Wikimedia Commons).
Image: GS4 prostate cancer: The tissue has few recognizable glands. Many cells are invading the surrounding tissue in neoplastic clumps. This corresponds to a poorly differentiated carcinoma (Photo courtesy of Wikimedia Commons).
Image: GS4 prostate cancer: The tissue has few recognizable glands. Many cells are invading the surrounding tissue in neoplastic clumps. This corresponds to a poorly differentiated carcinoma (Photo courtesy of Wikimedia Commons).
Cancer researchers have identified three mutations in the KLK3 (kallikrein-related peptidase 3) gene, which codes for prostate specific antigen (PSA), associated with biopsy-proven high-aggressive prostate cancer.

The three mutations or single nucleotide polymorphisms (SNPs) were among 72 prostate cancer susceptibility SNPs identified during genome-wide association studies of 1,827 white men with histologically confirmed prostate adenocarcinoma. SNPs associated with disease aggressiveness were identified by comparing high-aggressive (GS ≥8) and low-aggressive (GS ≤6) cases.

Investigators at The University of Texas MD Anderson Cancer Center (Houston, USA) reported that the three SNPs - rs2735839, rs10486567, and rs103294 -were associated with biopsy-proven high-aggressive (GS ≥8) prostate cancer. Furthermore, the frequency of the variant allele (A) at rs2735839 was significantly higher in patients with biopsy-proven GS4+3 disease than in those with GS3+4 disease.

The rs2735839 SNP is located 600 base pairs downstream of the KLK3 gene (encoding PSA) on chromosome 19q13.33 and has been shown to modulate PSA level, providing strong biologic plausibility for its association with prostate cancer aggressiveness.

The investigators also showed that rs2735839 could stratify patients with GS7 cancer, which is an intermediate grade of cancer accounting for 30 to 40% of all prostate cancers. This would be clinically important for more accurately assessing the clinical behavior of the intermediate-grade prostate cancer and for tailoring personalized treatment and post-treatment management.

"This is the first report that I am aware of that indicates a genetic variant can stratify GS7 prostate cancer patients," said contributing author Dr. Jian Gu, associate professor of epidemiology at the MD Anderson Cancer Center. "This is important because this group with heterogeneous prognosis is difficult to predict and there are no reliable biomarkers to stratify this group."

"Treatment options for the GS7 disease are controversial because the burden of combined treatment modalities may outweigh the potential benefit in some patients," said senior author Dr. Xifeng Wu, professor of epidemiology at the MD Anderson Cancer Center. "It is critical that we develop personalized treatments based on additional biomarkers to stratify GS7 prostate cancers. Additional biomarkers may help us achieve personalized clinical management of low and intermediate risk prostate cancer patients."

The study was published in the October 1, 2014, issue of the journal Clinical Cancer Research.

Related Links:
The University of Texas MD Anderson Cancer Center


New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette
New
Biological Indicator Vials
BI-O.K.

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.